F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. The orotomides have a distinct mechanism of action, selectively targeting fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway. This differentiates the orotomides from the currently marketed antifungal agents. Olorofim (formerly F901318) is F2G’s leading candidate from this class and has fungicidal activity against a broad range of mould infections including a variety of rare and resistant moulds that cause life-threatening infections for which current therapies have limitations or are ineffective. Olorofim is in a Phase 2b open-label study focusing on rare and resistant invasive fungal infections including invasive aspergillosis (including azole-resistant strains), coccidioidomycosis and scedosporiosis (including lomentosporiosis). Olorofim has received orphan drug status from the European Medicines Agency and orphan drug status, Qualified Infectious Disease Product (QIDP) designation and Breakthrough Therapy designation from FDA. F2G is headquartered in the UK with subsidiaries in the US and Austria.
View Top Employees from F2GWebsite | http://www.f2g.com |
Revenue | $10.7 million |
Funding | $247.9 million |
Employees | 97 (64 on RocketReach) |
Founded | 1998 |
Phone | +44 161 785 1270 |
Fax | +44 161 785 1273 |
Technologies |
HTML,
Slack,
Later
+3 more
(view full list)
|
Industry | Biotechnology Research, Education General, Biotechnology, Drug Discovery, Education, Science and Engineering, Pharmaceuticals, Genetics, Health Care, Medical, Pharmaceutical |
Web Rank | 4 Million |
Keywords | Clinical-Stage Biopharmaceutical Company |
Competitors | Affectis Pharmaceuticals, Amplyx, now a subsidiary of Pfizer Inc., Biokine Therapeutics Ltd., Step Pharma, Synairgen Research Ltd |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 54138 Companies, NAICS Code 5413 Companies, NAICS Code 541 Companies |
Looking for a particular F2G employee's phone or email?
The F2G annual revenue was $10.7 million in 2024.
Francesco Lavino is the CEO of F2G.
64 people are employed at F2G.
The NAICS codes for F2G are [54, 54138, 5413, 541].
The SIC codes for F2G are [873, 87].